Citation Information :
Kumar A, Saini V, Kaur J, Garg K, Gupta S, Kaur K. Serum Interleukin-33 and Soluble Suppression of Tumorigenicity 2 in Bronchial Asthma. Indian J Chest Dis Allied Sci 2019; 61 (4):171-174.
Background: Interleukin-33 (IL-33) is a member of IL-1 family of cytokines and is a ligand to the receptors of soluble suppression of tumorigenicity 2 (sST2). The IL-33/sST2 axis is involved in the promotion and maintenance of allergic inflammatory pathway in asthma; hence serum levels of these two biomarkers were studied.
Methods: This cross-sectional and observational study was conducted in Government Medical College and Hospital, Chandigarh, India. A total of 220 subjects were recruited and divided into four groups: Group A: asthmatic patients with exacerbation, Group B: asthmatic patients without exacerbation, Group C: patients with other lung diseases, like chronic obstructive pulmonary disease, community acquired pneumonia, lung cancer, etc and Group D: age and gender matched apparently healthy individuals and serum IL-33 and sST2 levels were studied.
Results: Present study showed that IL-33 and sST2 levels were significantly raised in asthmatic patients with acute exacerbation. Mean serum values of IL-33 were 37.9, 27.1, 15.2 and 14.5pg/mL in groups A, B, C and D, respectively and those of sST2 were 7.91, 7.03, 3.98 and 3.56 ng/mL in the groups A, B, C and D, respectively.
Conclusion: Serum IL-33 and sST2 can be considered as novel biomarkers in asthma severity.
Masoli M, Fabian D, Holt S. The Global initiative for Asthma program (GINA). The Global burden of asthma: Executive summary of the GINA Dissemination Committee Report. Allergy 2004;59:469–78.
Lai CK, Beasley R, Crane J. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood. Thorax 2009;64: 476–83.
Schmitz J, Owyang A, Oldham E. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479–90.
Kaiko G, Horvat J, Beagley K, Hansbro P. Immunological decision making: how does the immune system decide to mount a helper T-cell response. Immunology 2008;123:326–38.
Savenije OE, Kerkhof M, Reijmerink NE. Interleukin-1 receptorlike polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol 2011;127:750–6.
Pavord ID, Korn S, Howarth P. Mepolizumav for severe eosinophilic asthma: a multicentric, double-blind, placebocontrolled trial. Lancet 2012;380:651–9.
Noonan M, Korenvlat P, Mosesova S. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013;132:567–74.
Wenzel S, Ford L, Pearlman D. Dupilumav in persistant asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–66.
Oshikawa K, Kuroiwa K, Tago K. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277–81.
Préfontaine D, Lajoie KS, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183:5094–103.
Liu X, Li M, Yan W, Zhou C, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009;386:181–5.
Mato N, Bando M, Yamasawa H, Hosono T, Mizushina Y, Sata M, et al. Role of IL-33 in bronchial asthma. Nihon Kokyuki Gakkai Zasshi 2010;48:419–25.
Prefontaine D, Nadigel J, Chouiali F. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010;125:752–4.
Azazi EA, Elshora AE, Tantawy AE. Serum levels of interleukin-33 and its soluble receptor ST2 in asthmatic patients. Egyptian J Chest Dis Tuberc 2014;63:279–84.
Saglani S, Lui S, Ullmann N. IL-33 promotes airway remodeling in paediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013;132:676–85.
Hamzaoui A, Berraies A, Kaabachi W, Haifa M, Ammar J, Kamel H, et al. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children. J Asthma 2013;50:803–9.
Guo Z, Wu J, Zhao J, Liu F, Chen Y, Bi L, et al. IL-33 promotes airway remodelling and is a marker of asthma disease severity. J Asthma 2014;51:863–9.
Mahneh BS, Movahedi M, Aryan Z, Bahar AM, Rezaei A, Sadr M, et al. Serum IL-33 is elevated in children with asthma and is associated with disease severity. Int Arch Allergy Immunol 2015;168:193–6.
Li R, Yang G, Yang R, Peng X, Li J. Interleukin-33 and receptor ST2 as indicators in patients with asthma: a meta-analysis. Int J Clin Exp Med 2015;8:14935–43.
Wang Y, Wang L, Hua S. Interleukin-33 in children with asthma: a systematic review and meta-analysis. Allergol Immunopathol 2017;45:387–91.
GINA guidelines. Global initiative for asthma 2015. Available from URL: http://www.ginasthma.org. Accessed on October 10, 2016.
GOLD 2015, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease Updated 2015. Available from URL: http://www.goldcopd.org. Accessed on October 10, 2016.
British Thoracic Society, BTS guidelines for the management of community acquired pneumonia in adults 2009 update. Available from URL: http://www.britthoracic.org.uk. Accessed on October 10, 2016.
TB INDIA 2015, Revised National TB Control Programme 2015. Available from URL: http://www.tbcindia.nic.in. Accessed on October 10, 2016.
Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defence and diseases. Allergol Int 2010;59:143–60.
